| AYRMID |
AYRMID |
90%
|
we and Ayrmid entered into a transition services agreement pursuant to which we agreed to provide Ayrmid with certain services related to the development and commercialization of motixafortide within… |
| HONG-SENG-TECHNOLOGY-LIMITED |
HONG-SENG-TECHNOLOGY-LIMITED |
90%
|
On August 27, 2023, we entered into the Gloria License Agreement, with Hong Seng Technology Limited, or HST, and Gloria, and/or with HST, the Gloria Licensee, pursuant to which we granted HST an excl… |
| SNYNF |
Sanofi |
72%
|
l and the USA. We also claim common law protections for other marks we use in our business. Competitors and other companies could adopt similar marks or try to prevent us from using our marks, conseq… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from BLRX graph: l and the USA. We also claim common law protections for other marks we use in our business. Competitors and other co… |
| AMNEAL-EU-LTD-GLAND-PHARMA-LTD-HETERO-LABS-LTD |
AMNEAL-EU-LTD-GLAND-PHARMA-LTD-HETERO-LABS-LTD |
62%
|
imilar marks or try to prevent us from using our marks, consequently impeding our ability to build brand identity and possibly leading to customer confusion. 48 Manufacturing With respect to GLIX1, w… |
| AYRMID-PHARMA-LTD |
AYRMID-PHARMA-LTD |
62%
|
icensed product in this indication. Licensing rights for other indications and related support were deemed immaterial. F - 48 BioLineRx Ltd. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS NOTE 15 – L… |
| BIOKINE-THERAPEUTICS-LTD |
BIOKINE-THERAPEUTICS-LTD |
62%
|
th any product, manufacturer or manufacturing process, or failure to comply with regulatory requirements, may result in actions such as: • restrictions on such product, manufacturer or manufacturing … |
| BIOLINERX-USA-INC |
BIOLINERX-USA-INC |
62%
|
d often are not preempted by HIPAA, thus complicating compliance efforts. U.S. Healthcare Reform A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorit… |
| CO-LLC |
CO-LLC |
62%
|
that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, may result in increased pricing pressure by influencing, for instance, the reimbursement policies of third-party payo… |
| COORDINATION-GROUP |
COORDINATION-GROUP |
62%
|
imilar marks or try to prevent us from using our marks, consequently impeding our ability to build brand identity and possibly leading to customer confusion. 48 Manufacturing With respect to GLIX1, w… |
| HIGHBRIDGE-CAPITAL-MANAGEMENT-LLC |
HIGHBRIDGE-CAPITAL-MANAGEMENT-LLC |
62%
|
NOTE 11 – EQUITY (cont.) c. Changes in the Company’s equity (cont.) 4) In November 2024, the Company completed a registered direct offering to certain funds associated with Highbridge Capital Managem… |
| INNOVATIVE-PHARMACEUTICAL-CONCEPTS-INC |
INNOVATIVE-PHARMACEUTICAL-CONCEPTS-INC |
62%
|
th any product, manufacturer or manufacturing process, or failure to comply with regulatory requirements, may result in actions such as: • restrictions on such product, manufacturer or manufacturing … |
| LABORATORIES-LTD-TEVA-PHARMACEUTICALS-USA-INC |
LABORATORIES-LTD-TEVA-PHARMACEUTICALS-USA-INC |
62%
|
imilar marks or try to prevent us from using our marks, consequently impeding our ability to build brand identity and possibly leading to customer confusion. 48 Manufacturing With respect to GLIX1, w… |
| MEITHEAL-PHARMACEUTICALS-INC |
MEITHEAL-PHARMACEUTICALS-INC |
62%
|
imilar marks or try to prevent us from using our marks, consequently impeding our ability to build brand identity and possibly leading to customer confusion. 48 Manufacturing With respect to GLIX1, w… |
| MSN-LABORATORIES-PRIVATE-LTD-EUGIA-PHARMA-SPECIA |
MSN-LABORATORIES-PRIVATE-LTD-EUGIA-PHARMA-SPECIA |
62%
|
imilar marks or try to prevent us from using our marks, consequently impeding our ability to build brand identity and possibly leading to customer confusion. 48 Manufacturing With respect to GLIX1, w… |
| TETRAGON-BIOSCIENCES-LTD |
TETRAGON-BIOSCIENCES-LTD |
62%
|
th any product, manufacturer or manufacturing process, or failure to comply with regulatory requirements, may result in actions such as: • restrictions on such product, manufacturer or manufacturing … |
